{"filing":{"accession_number":"0001193125-26-391880","cik":"0001799448","ticker":"ALGS","company_name":"Aligos Therapeutics, Inc.","form":"8-K","filing_date":"2026-09-15","report_date":"2026-09-10","primary_document":"d120930d8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1799448/000119312526391880/d120930d8k.htm"},"events":[{"id":33595,"run_id":30896,"accession_number":"0001193125-26-391880","anchor_item_number":"1.01","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"summary":"Aligos entered into a First Amendment to its headquarters lease on September 10, 2026, extending the term from March 31, 2027 to March 31, 2034 with specified rent escalations and a ten-month rent abatement. While this is a material definitive agreement affecting the company's long-term occupancy of its headquarters, it is primarily an operational/real estate matter rather than a financial obligation (debt issuance), M\u0026A activity, or other specifically-named event type. The lease extension secures the company's primary office location for seven additional years and would be material to investors assessing operational continuity, but the event itself is a routine real estate transaction that does not fit the more specific financial or strategic categories.","company_name":"Aligos Therapeutics, Inc.","ticker":"ALGS","filing_date":"2026-09-15","form":"8-K","submitted_at":null,"items":[{"id":37079,"accession_number":"0001193125-26-391880","item_number":"1.01","item_title":"Entry into a Material Definitive Agreement.","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"Aligos entered into a First Amendment to its headquarters lease on September 10, 2026, extending the term from March 31, 2027 to March 31, 2034 with specified rent escalations and a ten-month rent abatement. While this is a material definitive agreement affecting the company's long-term occupancy of its headquarters, it is primarily an operational/real estate matter rather than a financial obligation (debt issuance), M\u0026A activity, or other specifically-named event type. The lease extension secures the company's primary office location for seven additional years and would be material to investors assessing operational continuity, but the event itself is a routine real estate transaction that does not fit the more specific financial or strategic categories.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-15T20:04:37.238104+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":37079,"accession_number":"0001193125-26-391880","item_number":"1.01","item_title":"Entry into a Material Definitive Agreement.","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"Aligos entered into a First Amendment to its headquarters lease on September 10, 2026, extending the term from March 31, 2027 to March 31, 2034 with specified rent escalations and a ten-month rent abatement. While this is a material definitive agreement affecting the company's long-term occupancy of its headquarters, it is primarily an operational/real estate matter rather than a financial obligation (debt issuance), M\u0026A activity, or other specifically-named event type. The lease extension secures the company's primary office location for seven additional years and would be material to investors assessing operational continuity, but the event itself is a routine real estate transaction that does not fit the more specific financial or strategic categories.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-15T20:04:37.238104+00:00","company_name":"Aligos Therapeutics, Inc.","ticker":"ALGS","filing_date":"2026-09-15"}]}